Masimo wins two OCTANE High Tech Awards - company recognized for 'Deal of the Year' and 'Best Technology Leadership Team' Sep 30, 2026, 09:05 ET IRVINE, Calif., Sept. 30, 2026 /PRNewswire/ - Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced that it received two honors at the 2026 Octane High Tech Awards, winning Deal of the Year and Best Technology Company Leadership Team. The awards recognize two significant milestones for Masimo: the company's $9.9 billion acquisition by Danaher and the leadership team guiding Masimo as it begins its next chapter as part of Danaher's Diagnostics platform. "The Deal of the Year recognition is meaningful, particularly given the strength of the medtech ecosystem here in Orange County, but I'm especially proud of the recognition of our leadership team," said Tim Benner, President of Masimo. "This is a group defined by patient-centricity, innovation and agility, and they have led through significant change while keeping our associates, customers and, most importantly, patients at the center of everything we do. I couldn't be prouder of this team and what we are building together." Benner continued, "We're also grateful to Octane for this recognition and for the important role it plays in bringing together and supporting Orange County's technology and medical technology community. Masimo has deep roots here, and we're proud to be part of a community that continues to advance innovation, entrepreneurship and technologies that can make a meaningful difference in people's lives." The Deal of the Year award recognized Danaher's $9.9 billion acquisition of Masimo, which was completed in June 2026. The Best Technology Company Leadership Team award recognizes a leadership team of a technology or medical technology company in Orange County. Masimo's leadership team was honored for its work leading the organization through a transformational period while maintaining focus on customers, innovation, operational excellence and improving patient outcomes. The Octane High Tech Awards celebrate companies and leaders contributing to Orange County's technology and medical technology ecosystem. Masimo is proud to join fellow innovators from across the region in recognizing the people and organizations helping strengthen Orange County as a center for technology and medical innovation. About Masimo Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is for our innovations to empower clinicians to transform patient care. Masimo SET(R) Measure-through Motion and Low Perfusion(TM) pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET(R) is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2026 Newsweek World's Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com. About Danaher Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges - helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our more than 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com. SOURCE Masimo Corporation

American Society of Anesthesiologists announces 14-year collaboration with Masimo as a Corporate Supporter. Newswise - CHICAGO - The American Society of Anesthesiologists (ASA) today announced the continuation of its longstanding collaboration with Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient-monitoring solutions, through ASA's Corporate Supporter Program. Now in its 14th year, the relationship supports education and initiatives designed to advance anesthesia care and help improve patient outcomes. "As an anesthesiologist, I understand the critical role that education, innovation, and reliable technology play in delivering the highest-quality patient care," said ASA President Patrick Giam, M.D., FASA. "We welcome Masimo's continued collaboration and support through the ASA Corporate Supporter Program. Working together, we will advance the specialty, provide anesthesiologists with valuable resources, and ultimately improve outcomes for the patients we serve." As a Corporate Supporter, Masimo continues to build on its longstanding relationship with the anesthesiology community, strengthen collaboration between anesthesiologists and industry, and add to the value the Society provides to members and their patients, while providing invaluable year-round support of ASA programs and priorities related to perioperative care. Corporate Supporters have unique opportunities to inform strategic dialogue with leaders in anesthesiology from around the world and during major ASA events including the ANESTHESIOLOGY(R) annual meeting and ADVANCE: The Anesthesiology Business Event. "Masimo has always believed that the best innovation starts with a deep understanding of clinicians and the patients they serve," said Tim Benner, president of Masimo. "For 14 years, our collaboration with ASA has given us an important opportunity to support the anesthesiology community through education, dialogue and shared learning. We're proud to continue that commitment as we work together to advance patient care and improve outcomes." Established in 2010, ASA's Corporate Supporter Program is limited to 10 organizations. The program recognizes leading companies that demonstrate a sustained commitment to advancing the specialty of anesthesiology through support of education, innovation, and initiatives that benefit anesthesiologists and the Anesthesia Care Team. ABOUT THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 60,000 members organized to advance the medical practice of anesthesiology and secure its future. ASA is committed to ensuring anesthesiologists evaluate and supervise the medical care of all patients before, during and after surgery. ASA members also lead the care of critically ill patients in intensive care units, as well as treat pain in both acute and chronic settings. ABOUT MASIMO Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is for our innovations to empower clinicians to transform patient care. Masimo SET(R) Measure-through Motion and Low Perfusion(TM) pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET(R) is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2026 Newsweek World's Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges - helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com. Media contact. Type OF article. Section.

Masimo has received FDA 510(k) clearance for Root with LiDCO and the Masimo LiDCO Sensor, enabling continuous monitoring of oxygen delivery (DO₂). The device combines LiDCO hemodynamic monitoring, noninvasive haemoglobin measurement (SpHb), and Masimo SET pulse oximetry to provide beat-to-beat assessment of oxygen delivery. The technology addresses a historical limitation in DO₂ monitoring, which previously relied on intermittent laboratory measurements of haemoglobin. By integrating cardiac output, haemoglobin, and oxygen saturation into a single continuous measure, the system offers clinicians real-time visibility into oxygen transport during surgery and periods of physiological stress. Masimo, a Danaher company, develops pulse oximetry and patient monitoring solutions. The clearance expands the company's monitoring portfolio by providing an integrated view of oxygen delivery to tissue.